Recombinant Interferon-Beta1a Use in Six Patients with Myeloproliferative Neoplasms: A First Impression
Abstract
Objective: Assess the safety and efficacy of recombinant interferon-beta1a (rIFN-β1a) in myeloproliferative neoplasm (MPN) patients transitioning from pegylated interferon-alpha2 (peg-IFN-α2).
Method: Retrospective review of six MPN patients switching to rIFN-β1a (44 mcg weekly).
Results: All patients reported myalgia. No other adverse events or treatment discontinuations. Reduced JAK2V617F allele burden in three patients.
Conclusion: rIFN-β1a demonstrated manageable safety in MPN patients, with potential efficacy. Larger studies are needed.
References
- Foucar CH, Stein BL. Contemporary use of interferon therapy in the myeloproliferative neoplasms. Current Hematologic Malignancy Reports. 2017;12:406-414. https://doi.org/10.1007/s11899-017-0402-1
- Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers. 2022;14(22):5495. https://doi.org/10.3390/cancers14225495
- Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225. https://doi.org/10.1182/blood-2011-11-394775
- Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–220. https://doi.org/10.1016/j.leukres.2012.10.020
- Pedersen RK, Andersen M, Knudsen TA, Sajiid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, et al. Data-driven analysis of JAKV617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020;9:2039–2051. https://doi.org/10.1002/cam4.2741
- Borden EC. Interferons α and β in cancer: Therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 2019;18:219–234. https://doi.org/10.1038/s41573-018-0011-2
- Platanias LC, Uddin S, Domanski P, Colamonici OC. Differences in Interferon α and β Signaling. J. Biol. Chem. 1996;271:23630–23633. https://doi.org/10.1074/jbc.271.39.23630
Abstract
Amaç: Pegile interferon-alfa2'den (peg-IFN-α2) geçiş yapan miyeloproliferatif neoplazm (MPN) hastalarında rekombinant interferon-beta1a'nın (rIFN-β1a) güvenliği ve etkinliği değerlendirildi.
Yöntem: Haftalık 44 mcg rIFN-β1a'ya geçen altı MPN hasta geriye dönük incelendi.
Bulgular: Tüm hastalar miyalji bildirdi. Başka hiçbir yan etki veya tedavi kesilmesi görülmedi. Üç hastada JAK2V617F alel yükünde azalma gözlendi.
Sonuç: rIFN-β1a, MPN hastalarında yönetilebilir güvenlilik göstermiştir ve potansiyel etkinliğe sahiptir. Daha büyük çalışmalara ihtiyaç vardır.
References
- Foucar CH, Stein BL. Contemporary use of interferon therapy in the myeloproliferative neoplasms. Current Hematologic Malignancy Reports. 2017;12:406-414. https://doi.org/10.1007/s11899-017-0402-1
- Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers. 2022;14(22):5495. https://doi.org/10.3390/cancers14225495
- Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225. https://doi.org/10.1182/blood-2011-11-394775
- Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–220. https://doi.org/10.1016/j.leukres.2012.10.020
- Pedersen RK, Andersen M, Knudsen TA, Sajiid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, et al. Data-driven analysis of JAKV617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020;9:2039–2051. https://doi.org/10.1002/cam4.2741
- Borden EC. Interferons α and β in cancer: Therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 2019;18:219–234. https://doi.org/10.1038/s41573-018-0011-2
- Platanias LC, Uddin S, Domanski P, Colamonici OC. Differences in Interferon α and β Signaling. J. Biol. Chem. 1996;271:23630–23633. https://doi.org/10.1074/jbc.271.39.23630
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Letter to Editor |
| Authors | |
| Submission Date | February 25, 2025 |
| Acceptance Date | April 10, 2025 |
| Publication Date | April 29, 2025 |
| DOI | https://doi.org/10.56016/dahudermj.1647004 |
| IZ | https://izlik.org/JA42BF69HM |
| Published in Issue | Year 2025 Volume: 5 Issue: 2 |